Noah L. Rosenberg

Noah L. Rosenberg, listed as senior executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Travere Therapeutics, Inc. and Verrica Pharmaceuticals Inc. We count 29 filings; the first trade dates from 26 July 2018 and the latest from 18 August 2026.

On the open market, the record shows 3 purchases worth €35k and 17 sales worth €313k. On balance, insiders were net sellers of €278k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 9 share grants. In 2026 alone, the filings show 2 purchases and no sales.

In size, the median ticket on the buying side is €8,680. Of 3 purchases, 3 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

Most recently, on 18 August 2026, the filings show an open-market purchase worth €8,620 in Verrica Pharmaceuticals Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.